WHO 2024 Hepatitis B Guidelines and Treatment-Eligible Rate Among Treatment-Naive Patients

Jian Wang; Shaoqiu Zhang; Chuanwu Zhu; Chao Wu; Rui Huang

doi:10.1001/jamanetworkopen.2024.35777

WHO 2024 Hepatitis B Guidelines and Treatment-Eligible Rate Among Treatment-Naive Patients

JAMA Netw Open. 2024 Sep 3;7(9):e2435777. doi: 10.1001/jamanetworkopen.2024.35777.

Authors

Jian Wang^{1

2}, Shaoqiu Zhang¹, Chuanwu Zhu³, Chao Wu^{1

2}, Rui Huang^{1

2}

Affiliations

¹ Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
² Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
³ Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.

No abstract available

Plain language summary

This cross-sectional study compares rates of hepatitis B treatment eligibility among treatment-naive patients according to the World Health Organization (WHO) 2024 guidelines with eligibility rates across other international guidelines.

MeSH terms

Adult
Antiviral Agents / therapeutic use
Female
Hepatitis B / drug therapy
Humans
Male
Middle Aged
Practice Guidelines as Topic*
World Health Organization*

Substances

Antiviral Agents